June 5, 2017 / 12:26 PM / 3 months ago

BRIEF-Blueprint Medicines announces new phase 1 clinical data for Blu-285

June 5 (Reuters) - Blueprint Medicines Corp:

* Blueprint medicines announces new phase 1 clinical data for Blu-285 in advanced gastrointestinal stromal tumors and plans to pursue expedited development in patients with a pdgfrα d842v mutation

* ‍Blu-285 was well tolerated, and most adverse events reported by investigators were grade 1 or 2.​

* FDA granted breakthrough therapy designation to Blu-285 for treatment of patients with unresectable or metastatic pdgfrα d842v-driven gist​

* ‍Additional data from expansion portion of ongoing trial of Blu-285 may be sufficient to support nda for treatment of patients with pdgfrα d842v-driven gist

* ‍company also plans to initiate a global, pivotal phase 3 clinical trial of Blu-285 in first half of 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below